These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 30565812)

  • 1. Study of the NR4A family gene expression in patients with multiple sclerosis treated with Fingolimod.
    Montarolo F; Perga S; Martire S; Brescia F; Caldano M; Lo Re M; Panzica G; Bertolotto A
    Eur J Neurol; 2019 Apr; 26(4):667-672. PubMed ID: 30565812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered NR4A Subfamily Gene Expression Level in Peripheral Blood of Parkinson's and Alzheimer's Disease Patients.
    Montarolo F; Perga S; Martire S; Navone DN; Marchet A; Leotta D; Bertolotto A
    Neurotox Res; 2016 Oct; 30(3):338-44. PubMed ID: 27159982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting therapeutic response to fingolimod treatment in multiple sclerosis patients.
    Quirant-Sánchez B; Hervás-García JV; Teniente-Serra A; Brieva L; Moral-Torres E; Cano A; Munteis E; Mansilla MJ; Presas-Rodriguez S; Navarro-Barriuso J; Ramo-Tello C; Martínez-Cáceres EM
    CNS Neurosci Ther; 2018 Dec; 24(12):1175-1184. PubMed ID: 29656444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Selective Agonist for Sphingosine-1-Phosphate Receptors Siponimod Increases the Expression Level of
    Montarolo F; Martire S; Marnetto F; Valentino P; Valverde S; Capobianco MA; Bertolotto A
    Curr Issues Mol Biol; 2022 Mar; 44(3):1247-1256. PubMed ID: 35723306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of expression profile of microRNAs in multiple sclerosis patients treated with fingolimod.
    Mazdeh M; Kordestani H; Komaki A; Eftekharian MM; Arsang-Jang S; Branicki W; Taheri M; Ghafouri-Fard S
    J Mol Neurosci; 2020 Aug; 70(8):1274-1281. PubMed ID: 32215780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod.
    Song ZY; Yamasaki R; Kawano Y; Sato S; Masaki K; Yoshimura S; Matsuse D; Murai H; Matsushita T; Kira J
    PLoS One; 2014; 10(4):e0124923. PubMed ID: 25919001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline Differences in Minor Lymphocyte Subpopulations may Predict Response to Fingolimod in Relapsing-Remitting Multiple Sclerosis Patients.
    Teniente-Serra A; Hervás JV; Quirant-Sánchez B; Mansilla MJ; Grau-López L; Ramo-Tello C; Martínez-Cáceres EM
    CNS Neurosci Ther; 2016 Jul; 22(7):584-92. PubMed ID: 27080413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod.
    Koch-Henriksen N; Magyari M; Sellebjerg F; Soelberg Sørensen P
    Mult Scler; 2017 Feb; 23(2):234-241. PubMed ID: 27055806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-life long-term effectiveness of fingolimod in Swiss patients with relapsing-remitting multiple sclerosis.
    Zecca C; Roth S; Findling O; Perriard G; Bachmann V; Pless ML; Baumann A; Kamm CP; Lalive PH; Czaplinski A
    Eur J Neurol; 2018 May; 25(5):762-767. PubMed ID: 29431876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HDAC3-Mediated Repression of the
    Kwapis JL; Alaghband Y; López AJ; Long JM; Li X; Shu G; Bodinayake KK; Matheos DP; Rapp PR; Wood MA
    J Neurosci; 2019 Jun; 39(25):4999-5009. PubMed ID: 31000586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptomic Analysis Shows Decreased Cortical Expression of NR4A1, NR4A2 and RXRB in Schizophrenia and Provides Evidence for Nuclear Receptor Dysregulation.
    Corley SM; Tsai SY; Wilkins MR; Shannon Weickert C
    PLoS One; 2016; 11(12):e0166944. PubMed ID: 27992436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to Fingolimod in Multiple Sclerosis Patients Is Associated with a Differential Transcriptomic Regulation.
    Sánchez-Sanz A; Muñoz-Viana R; Sabín-Muñoz J; Moreno-Torres I; Brea-Álvarez B; Rodríguez-De la Fuente O; García-Merino A; Sánchez-López AJ
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptome profiling of peripheral blood immune cell populations in multiple sclerosis patients before and during treatment with a sphingosine-1-phosphate receptor modulator.
    Angerer IC; Hecker M; Koczan D; Roch L; Friess J; Rüge A; Fitzner B; Boxberger N; Schröder I; Flechtner K; Thiesen HJ; Winkelmann A; Meister S; Zettl UK
    CNS Neurosci Ther; 2018 Mar; 24(3):193-201. PubMed ID: 29314605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptional Profiling of Monocytes Deficient in Nuclear Orphan Receptors
    Phelan DE; Shigemura M; Aldhafiri S; Mota C; Hall TJ; Sznajder JI; Murphy EP; Crean D; Cummins EP
    Front Immunol; 2021; 12():676644. PubMed ID: 34248958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cryptococcal meningitis in a multiple sclerosis patient treated with Fingolimod: a case report and review of imaging findings.
    Chong I; Wang KY; Lincoln CM
    Clin Imaging; 2019; 54():53-56. PubMed ID: 30544079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The nuclear orphan receptor NR4A1 and NR4A3 as tumor suppressors in hematologic neoplasms.
    Wenzl K; Troppan K; Neumeister P; Deutsch AJ
    Curr Drug Targets; 2015; 16(1):38-46. PubMed ID: 25410408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-Resolution Expression Profiling of Peripheral Blood CD8
    Roch L; Hecker M; Friess J; Angerer IC; Koczan D; Fitzner B; Schröder I; Flechtner K; Thiesen HJ; Meister S; Winkelmann A; Zettl UK
    Mol Neurobiol; 2017 Sep; 54(7):5511-5525. PubMed ID: 27631876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The expression analyses of RMRP, DDX5, and RORC in RRMS patients treated with different drugs versus naïve patients and healthy controls.
    Rahmani S; Noorolyai S; Ayromlou H; Khaze Shahgoli V; Shanehbandi D; Baghbani E; Abdoli Shadbad M; Jigari-Asl F; Khamiriyan M; Safaralizadeh R; Baradaran B
    Gene; 2021 Feb; 769():145236. PubMed ID: 33068674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fingolimod as a first- or second-line treatment in a mini-series of young Hellenic patients with adolescent-onset multiple sclerosis: focus on immunological data.
    Gontika M; Skarlis C; Markoglou N; Evangelopoulos ME; Velonakis G; Chrousos GP; Dalakas M; Stefanis L; Anagnostouli M
    Neurol Sci; 2022 Apr; 43(4):2641-2649. PubMed ID: 34596776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of fingolimod on CD4+ T cell subset and cytokine profile of relapsing remitting multiple sclerosis patients.
    Kürtüncü M; Yılmaz V; Akçay Hİ; Türkoğlu R; Altunrende B; Çınar SA; Ulusoy C; Gündüz T; İçöz S; Kasap M; Çalışkan Z; Ötünç G; Eraksoy M; Tüzün E
    J Neuroimmunol; 2019 Dec; 337():577065. PubMed ID: 31526917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.